Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) platform technology to address gaps in cancer care, today joins the academic community in congratulating laureates of the 2022 Nobel Prize in Chemistry. Acepodia’s core technology, ACC, is inherited from Dr. Carolyn Bertozzi’s pioneering work in the development of biorthogonal chemistry which moves click chemistry into living organisms. The creation of Acepodia’s technology platform and its intellectual properties were one of the...